Diligence memo · auto-generated · as of July 2, 2026
Nervgen Pharma Corp.
Nervgen Pharma Corp. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Nervgen Pharma Corp. operates in Pharma, based in VANCOUVER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nervgen Pharma Corp. has raised $6.2M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.2M on 2020-08-10.
Most recent recorded round closed around 2021-11-29.
Valuation (modeled)modeled
Provath models Nervgen Pharma Corp. at approximately $12M (range $493K–$64M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.21× the median modeled value of Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 4.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 57% of Pharma peers (310 compared).
Modeled value ranks above 37% of those peers.
Closest niche peers: Zoo Pharma Dynamics Inc., Pharma-Labs Finance LLC, FSD Pharma Inc., Deepbiome Therapeutics, Inc., Pykus Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.